

the non-invasive breath analyzer platform

a breakthrough in diabetes history



Ben Delhey CEO

•::::BOYDSense







Pain points of today`s blood glucose monitoring...

537 million people with diabetes around the world in 2021*

Current technologies are painful (Blood Glucose Monitoring)





Highly invasive



Expensive



Impacting the Nature


Resulting in

Poor Adoption & Poor Diabetes Management

*IDF Atlas 2021



Lassie, the Perfect Platform For People Living With Type 2 Diabetes










Lassie will shake up glucose monitoring market for T2D*



Launch in 2025

Lassie will replace BGM (Blood Glucose Monitoring)



^{***} France, Germany, Spain, Italy, Benelux, UK






^{*} Type 2 Diabetes

^{**} Fortune Business Insights

Opportunity to be the first mover



Business model Legal Manufacturer





A powerful ecosystem

supports lassie









Tardy



Financial partner









Medical Advisors



Dr. Guido Freckman



Steven Chen



Timothy Garvev



William **Polonsky**



Example letter of intent (33)







pronovaBKK

Partner fur Ihre Gesundheit











Support needed to bring Lassie to life





Investor ask

€ 5M

- + € 2.5M EIC non- dilutive grant
- + € 2.5M EIC equity option (Phase 1*)



A strong and very experienced team



Average 25 years of experience in

- Commercialization of devices
- Volatile Organic Compounds (VOC)
- Breath Analysis
- Device Development and Miniaturisation
- Mass Volume Production
- 6 FTE year to date







Sandrine Isz, PhD CSO





key contact

Ben Delhey | CEO Boydsense

- in https://www.linkedin.com/in/ben-delhey/
- ben.delhey@boydsense.com
- +49 (0) 163/5570055